GT Biopharma (GTBP) Stock Price, News & Analysis

Company Overview

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS). Beyond GTB-3550, GT Biopharma is advancing a pipeline of preclinical TriKE constructs aimed at both hematologic and solid tumors, as well as exploring applications in infectious diseases. The modular nature of the TriKE platform enables rapid development of new molecules targeting diverse antigens, supporting strategic combination therapies and expansion into multiple oncology indications.

Founded in 2015 with technology originally licensed from the National Institutes of Health, GT Biopharma is headquartered in Tempe, Arizona, and conducts research and development operations in the United States. The company collaborates with leading academic institutions and global clinical sites to advance its pipeline. Under the leadership of President and CEO Scott K. Koenig, GT Biopharma continues to pursue its mission of delivering next-generation cell-engaging therapies to improve outcomes for patients with cancer and beyond.

Key Stats

• Today's Range: $0.64 to $0.77
• 50-Day Range: $0.58 to $1.83
• 52-Week Range: $0.55 to $4.10
• Volume: 1.56 million shs
• Average Volume: 4.30 million shs
• Market Capitalization: $2.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Moderate Buy

GT Biopharma Stock Analysis - MarketRank™

GT Biopharma scored higher than 38% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

GT Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

GT Biopharma has a consensus price target of $11.00, representing about 1,517.9% upside from its current price of $0.68.

Amount of Analyst Coverage

GT Biopharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for GT Biopharma are expected to grow in the coming year, from ($6.79) to ($2.11) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GT Biopharma is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of GT Biopharma is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.66% of the float of GT Biopharma has been sold short.

Short Interest Ratio / Days to Cover

GT Biopharma has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GT Biopharma has recently increased by 63.66%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GT Biopharma does not currently pay a dividend.

Dividend Growth

GT Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.66% of the float of GT Biopharma has been sold short.

Short Interest Ratio / Days to Cover

GT Biopharma has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GT Biopharma has recently increased by 63.66%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.68

News Sentiment

GT Biopharma has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for GT Biopharma this week, compared to 0 articles on an average week.

Search Interest

5 people have searched for GTBP on MarketBeat in the last 30 days.

MarketBeat Follows

5 people have added GT Biopharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, GT Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.40% of the stock of GT Biopharma is held by insiders.

Percentage Held by Institutions

Only 8.15% of the stock of GT Biopharma is held by institutions.

GTBP Stock Analysis - Frequently Asked Questions

How have GTBP shares performed this year?

GT Biopharma's stock was trading at $3.05 at the beginning of the year. Since then, GTBP shares have decreased by 77.7% and is now trading at $0.6799.

How were GT Biopharma's earnings last quarter?

GT Biopharma, Inc. (NASDAQ:GTBP) posted its quarterly earnings results on Thursday, August, 14th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.13.

When did GT Biopharma's stock split?

Shares of GT Biopharma reverse split on the morning of Monday, February 5th 2024.The 1-30 reverse split was announced on Monday, February 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of GT Biopharma?

Shares of GTBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of GT Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GT Biopharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), Meta Platforms (META), CrowdStrike (CRWD) and Intel (INTC).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 10/11/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GTBP
• Previous Symbol: OTCMKTS:OXISD
• CIK: 109657
• Web: www.gtbiopharma.com
• Phone: (415) 919-4040
• Fax: N/A
• Employees: 8
• Year Founded: 1965

Price Target and Rating

• Average Price Target for GT Biopharma: $11.00
• High Price Target: $11.00
• Low Price Target: $11.00
• Potential Upside/Downside: +1,517.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.16 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1,804.34%
• Return on Assets: -200.12%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.76
• Quick Ratio: 2.76

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.75) per share
• Price / Book: -0.91

Miscellaneous

• Outstanding Shares: 3,560,000
• Free Float: 3,436,000
• Market Cap: $2.42 million
• Optionable: No Data
• Beta: 1.32